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ABSTRACT 
 
Of the millions of Americans with heart failure, a significant portion are end-stage 
and experience symptoms even at rest.  Moreover, around half of people with heart failure 
die within 5 years of diagnosis.  The ideal treatment option for these patients is a heart 
transplant.  However, fewer than 3000 donor hearts are available for transplant in North 
America each year.  Given the significant disparity in number of donor hearts and end-
stage failure patients, there is great clinical need for heart assist technology that supports 
heart function, and for improved approaches that lead to heart recovery.   
The current leading device therapy for advanced heart failure patients is a 
Ventricular Assist Device (VAD).  While these devices have been clinically available in 
the United States since 2003, they are associated with severe complications – including a 
high risk for stroke and gastrointestinal bleeding.  As an alternative to mechanical blood 
pumps, direct cardiac compression (DCC) devices have been developed for heart assist.  
The investigation described herein includes the development, simulation, and preclinical 
testing of a novel DCC device – coined the EpicHeart™ (Epicardial Heart Assist Device).  
First, engineering design improvements were required to allow for synchronization 
between device activation and the native contraction of the heart.  The methods to 
accomplish this goal are described with results of in vivo testing.  Then, the hemodynamic 
effects of the device in an acute heart failure model were investigated.  Finally, the results 
of the in vivo testing of the device were applied for technical specification verification of 
a simulation platform developed to model the clinical effects of the EpicHeart™ Device.   
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The outcomes of this study have yielded an improved preclinical medical device 
that will proceed with future investigations over longer study durations as well as other 
heart failure etiologies – while continuing to explore potential for heart recovery.  
Additionally, the pilot study of simulating this technology is unique and has provided 
support for future validation of a clinical simulation tool.  This simulation is anticipated 
for use in a clinical environment to predict patient outcomes of the EpicHeart™ Device 
for treatment of heart disease.  
 iv 
 
DEDICATION 
 
This work is dedicated to my family, especially my parents Rick and Michele 
Hord.  Together you have inspired me to want to make a difference in medicine, and have 
always encouraged my scientific curiosity.  I am grateful for all that you have done to 
support my engineering education, and my career as a professional student.   
To my siblings, Megan, Natalie, Krista, and Ricky, I am thankful for your comic 
relief, and admittedly a little friendly competition that always pushes us to achieve more.  
I am proud of all of you.   
Finally, thank you to all of my grandparents.  You have taught us to work hard for 
what we want in life, and I am thankful for all that I have learned from you.  I wish you 
were all still here to see this work completed.  I love and miss you.         
 
 
 v 
 
ACKNOWLEDGEMENTS 
 
First and foremost, I would like to thank my committee members for their 
contributions and guidance.  Thank you to Dr. Moreno and Dr. Quick for what I have 
learned during my graduate courses, and for your guidance in my research.  Thank you to 
Dr. Tuzun for your continued support and everything you have taught me about preclinical 
studies.  Thank you to Dr. Bolch for your friendship and mentorship.  Finally, thank you 
to Dr. Criscione for giving me the opportunity to work under your guidance.  I am so 
grateful for how much I have learned from you over the past five years.   
I would also like to thank the staff members at the Texas A&M Institute for 
Preclinical Studies and the Texas Heart Institute for your contributions to our studies.  
Additionally, thank you to the CorInnova employees and Dr. Daniel Burkhoff for your 
support of this work.    
Finally, I cannot say thank you enough to my friends Megan, Jessi, Nichole, 
Nicole, Amanda, Andrea, Briana, and Elyse for your support throughout my nine-year 
career as a professional student.  I would not have made it without you.   
  
 vi 
 
CONTRIBUTORS AND FUNDING SOURCES 
 
Contributors 
This work was supervised by a dissertation committee consisting of Dr. John C. 
Criscione, Dr. Michael R. Moreno, and Dr. Egemen Tuzun of the Biomedical Engineering 
Department, Professor Christopher M. Quick of the Department of Veterinary Physiology 
and Pharmacology, and Dr. Christina M. Bolch, Senior Biomedical Engineer of 
CorInnova, Incorporated. 
The simulation outputs used for analysis in Section III were compiled by Reagan 
Tompkins of the Biomedical Engineering Department, and the simulation application was 
provided by Dr. Daniel Burkhoff of the Cardiovascular Research Foundation. 
All other work conducted for the dissertation was completed by the student, in 
collaboration with CorInnova, Incorporated.     
Funding Sources 
Graduate study was supported by a fellowship from the Texas A&M Engineering 
Experiment Station, a teaching fellowship from the Texas A&M University Biomedical 
Engineering Department, and through an internship with CorInnova, Incorporated.  This 
work was funded by The Wellcome Trust, Translation Fund Award no. 104613, awarded 
to CorInnova, Incorporated.  The contents of this document are solely the responsibility 
of the authors and do not necessarily represent the official views of The Wellcome Trust.  
  
 vii 
 
NOMENCLATURE 
 
AoP  Aortic Pressure 
BPM Beats Per Minute 
CO Cardiac Output 
CRI  Continuous Rate of Infusion 
CVP Central Venous Pressure 
DBP Diastolic Blood Pressure 
ECG Electrocardiogram 
ED End-Diastolic 
EDP End-Diastolic Pressure 
EDPVR End-Diastolic Pressure Volume Relationship 
EDV End-Diastolic Volume 
EHI EpicHeart™ Implantable 
EHDP EpicHeart™ Device Pressure 
EF Ejection Fraction 
ES End-Systolic 
ESP End-Systolic Pressure 
ESPVR End-Systolic Pressure Volume Relationship 
ESV End-Systolic Volume 
HR Heart Rate 
IABP Intra-Aortic Balloon Pump 
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LV Left Ventricle 
LVSW Left Ventricular Stroke Work 
LVSV Left Ventricular Stroke Volume 
LVP Left Ventricular Pressure 
MAP Mean Arterial Pressure 
PADP Pulmonary Artery Diastolic Pressure 
PAMP Pulmonary Artery Mean Pressure 
PASP Pulmonary Artery Systolic Pressure 
PV Pressure-Volume 
RV Right Ventricle 
SBP Systolic Blood Pressure 
SV Stroke Volume 
SW Stroke Work 
VAD Ventricular Assist Device 
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1. INTRODUCTION: THE NEED FOR HEART FAILURE THERAPY 
 
1.1. Heart Failure: Prevalence, Cost, and Pathology 
Heart failure (HF) is a chronic, progressive condition in which the pumping 
capacity of the heart has declined to a point where it cannot meet the blood and oxygen 
demands of the body.  This condition is a major public health issue, with over 6.5 million 
Americans currently living with HF, and 960,000 new cases diagnosed annually.1  
Moreover, it is projected that the prevalence of HF will increase by 46% from 2012 to 
2030, resulting in more than 8 million adults with HF.1 In addition to the high incidence 
rate, the prognosis of heart failure is poor; approximately 50% of people diagnosed with 
heart failure will die within 5 years.1   The annual mortality where heart failure was the 
underlying cause was over 68,000 in 2014, with the number of any-mention deaths 
attributable to HF at 309,000.1  From a financial standpoint, economic reports estimate 
that the total cost was $30.7 billion in 2012, with 68% of the total attributable to direct 
medical costs.1  Moreover, projections show that by 2030, the total cost of HF will increase 
almost 127% to $69.7 billion.1  
The development of this condition is usually initiated by a specific cardiac event, 
such as myocardial infarction, that causes a reduction in the contractile strength of the 
heart.  The heart compensates for its weakened state by Frank-Starling mechanisms as a 
result of renin-angiotensin retention of salt and water by the kidneys to increase total blood 
volume.  However, the increase in hydrostatic pressure impairs venous return to the heart, 
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further increasing the load on the heart.  Eventually, the ventricles begin to dilate in order 
to relieve abnormal mechanical stresses.  This pathological remodeling process results in 
a significantly reduced ventricular wall thickness with myocyte slippage, and an increase 
in the end-diastolic volume of the ventricle.  The dilated ventricle becomes more spherical 
in geometry, and combined with the thinning wall, the wall stress is significantly 
increased, culminating in a condition known as dilated cardiomyopathy.2-6 
Current pharmacological therapies, such as ACEIs and β-Blockers, used to 
symptomatically treat HF have a significant positive effect on morbidity and mortality.7  
However, these drug regimens fail to address the remodeling tissue, and eventually lose 
efficacy.  Surgery is not commonly used for early HF treatment, unless a correctable 
problem can be identified, such as aortic stenosis, mitral valve regurgitation, or coronary 
artery occlusion.  In cases of post-myocardial infarction, the tissue necrosis extends 
beyond the infarcted area, and cannot be remedied via surgical methods.   
As the condition progresses beyond the help of drug therapy, the patient reaches 
end-stage heart failure, a state at which the patient experiences symptoms even while at 
rest.   
1.2. Ideal Treatment: Heart Transplant 
The ideal treatment for end-stage HF patients is a heart transplant, with a 11-year 
median survival after receiving a new heart.8  However, fewer than 3,000 transplants are 
performed annually in North America.8  Additionally, transplant recipients are limited by 
multiple contraindications disqualifying a patient from receiving a donor heart.9  Those 
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patients who receive a heart transplant must be prescribed life-long immunosuppressant 
drugs, and are at risk for complications such as organ rejection and transplant coronary 
allograft vasculopathy.  Given the significant disparity in available donor hearts and 
patients in need, an alternative therapy is required. 
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2. EVALUATION OF THE EPICHEART™ ASSIST DEVICE IN AN ACUTE 
HEART FAILURE MODEL   
 
While it is expected that the most dramatic effects from the EpicHeart™ Device 
will be observed in chronic heart failure subjects, further testing in the acute stages is 
necessary to refine the designs, explore possible indications for use, and examine the 
potential conditions for optimal heart assist.  This section describes the results of in vivo 
device testing in an ovine acute HF model.  
2.1. Introduction 
Of the 6.5 million Americans with heart failure, a significant portion are end-stage 
and experience symptoms even at rest.1  The ideal treatment option for these patients is a 
heart transplant, with a 11-year median survival after receiving a new heart.8  However, 
fewer than 3,000 donor hearts are available for transplant in North America each year.8  
Given the significant disparity in number of donor hearts and end-stage failure patients, 
there is great clinical need for heart assist technology that supports heart function, and for 
improved approaches that lead to heart recovery.  As discussed by Moreno et al and 
advanced in the recent study by Roche et al, a properly designed direct cardiac 
compression (DCC) device that corrects aberrant heart motions and enhances heart 
contractility may be able to provide both heart assist and a potential means to enable heart 
recovery—provided that proper deformation of myocardium is needed for heart tissue 
growth and remodeling.10-12  
 5 
 
The results in the Moreno single animal studies demonstrate the possibility of 
restoring proper cardiac kinematics with a soft DCC implanted through a less invasive 
procedure than standard open heart surgery.10,11  This report furthers this work with design 
improvements (eliminating the need for guidewires in the deployment) and with multiple 
studies in an ovine model of acute heart failure (5 sheep with esmolol overdose).  
2.2. Materials and Methods 
2.2.1. EpicHeart™ Cardiac Assist Device 
The EpicHeart™ is a cardiac assist device that applies direct cardiac compression 
to the outside of the heart (epicardium) in synchrony with systole. The method of cardiac 
assist employed by the EpicHeart™ Implantable (EHI) is a unique combination of “active” 
assist, applied during systole with air infused into multiple bladders connected together in 
the form of a cup shape, in conjunction with a “passive” component that is in direct contact 
with the epicardium.13  The passive component consists of fluid-filled bladders that 
accommodate any gaps in the interface between the device and heart, while also enabling 
the heart to twist relative to the active component during contraction. All chambers of the 
EHI are constructed from thin-film thermoplastic polyurethane material.  The EHI is 
supported by a superelastic Nitinol wire frame, and is compressed into a cylinder 
(deployment tube) for minimally invasive deployment around the heart. See Figure 1 for 
fluoroscopic images showing the EHI implanted about the heart with contrast media in the 
passive chamber and air in the active component. 
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The EHI was operated using a custom programmable drive system – henceforth 
referred to as the Driver.  The ovine ECG was acquired using epicardial electrodes, and 
was gated by a custom-gain cardiac trigger monitor (Model 7700, IVY Biomedical).  
Using a custom programmable controller, the gated ECG signal is used to trigger the 
activation of solenoid valves, which were tailored to modulate the pressure of the active 
chambers in synchrony with systole.  A Millar Mikro-Tip® Catheter Pressure Transducer 
(Model SPR-320, Size 2F) was used to measure the fluid pressure in the passive chambers, 
providing a metric of epicardial assist pressure.  The EHI was activated for short periods 
of time (<5min) during this study with intermittent periods of device standby to observe 
the acute effects of EHI assist.  
Figure 1.  Fluoroscopic images of the EHI during standby (A), and during systolic assist (B); imaging 
contrast media was used as the fluid in the passive chambers for visual aid (darkest regions)  
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2.2.2. Study Design and Surgical Procedure 
Five (5) separate acute ovine, non-GLP studies were conducted for this 
investigation.  All experiments were conducted under an Animal Use Protocol (AUP) that 
was approved by the Texas A&M University Institutional Animal Care and Use 
Committee (IACUC) or the Texas Heart Institute IACUC.  Each study utilized a single, 
anesthetized adult domestic cross ovine (50-78 kg).  Upon induction of anesthesia, 
catheters were placed to facilitate the administration of medications as well as for 
monitoring of vital parameters.  AoP and LVP were monitored by either fluid-filled 
catheters or a Millar Mikro-Tip® Catheter Dual Pressure Transducer (SPR-751) placed 
across the aortic valve.  A Swan-Ganz (Edwards Lifesciences) catheter was used to 
measure the CVP and PAP.  A left-thoracotomy was performed to expose the aorta, 
without opening the pericardium, and a Transonic COnfidence Flowprobe® was placed 
around the ascending aorta to monitor CO before closing the incision.  
An apical approach was achieved through a subxyphoid incision with 
xyphoidectomy.  After performing the xyphoidectomy, the surgeon opened a small 
(approximately 1 in. diameter) circular incision at the pericardial apex, and then 
constructed a pericardial cradle to stabilize the pericardial edges.  A pericardiogram was 
performed for imaging of the epicardial structures by infusing contrast media directly into 
the pericardial sac through the apical hole.14  Prior to deployment, the EHI was loaded into 
a deployment tube (PTFE 2.5 cm OD, 2.3 cm ID, 20 cm  Length), with radiopaque marker 
tape used to visualize the distal end of the tube under fluoroscopic imaging (Indicator® 
1.0mm Lines – IZI Medical Products).  To prepare for implantation, the deployment tube 
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was placed inside the pericardial sac to align the fluoroscopy C-arm with the plane of the 
device; the radiopaque indicator lines provided a reference for the plane, with proper 
positioning defined as a field of view normal to the deployment tube.  The EHI was then 
advanced from the deployment tube around the heart under fluoroscopic guidance, inside 
the pericardium (Figure 2).  Once the EHI was in place around the heart (with positioning 
verified by fluoroscopy), the deployment tube was retracted, and the pneumatic driveline 
was tunneled to exit through the sternal incision before closing.  After removing air in the 
chest via a chest tube, the passive chamber of EHI was filled with an appropriate volume 
of imaging contrast media such that the peak pressure measured in the passive chambers 
during device standby reflected the ventricular end-diastolic pressure.  Finally, after filling 
the passive chamber and connecting the epicardial electrodes, assist was initiated at a low 
pressure to confirm stable ECG gating.  The amount of assist was increased until no 
adverse effects of additional air infusion were observed, such as pre-ventricular 
contractions (PVC).  
A high dose of esmolol was utilized to model acute heart failure. In addition to 
creating a stable, dose-dependent failure, esmolol has the benefit of rapid metabolism with 
a clearance half-life of only 9 min – allowing for rapid return to the baseline state.15  After 
all measurements were collected during the animal’s baseline state, an appropriate 
combination of bolus (20-150 mg) and continuous rate of infusion (CRI) (10-300 mL/hr, 
[10mg/mL]) was administered to target a 50% reduction in CO.  The dose varied with 
each animal, and was managed by the animal anesthesia staff. 
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Figure 2.  Fluoroscopic imaging of minimally invasive deployment of the EHI; initial advancement 
from the deployment tube, inside the apex of the pericardium (A), progressive stages of deployment 
(B, C), and the EHI in place around the heart, inside the pericardium (D) 
 10 
 
2.2.3. Data Collection and Statistical Analysis 
ADInstruments PowerLab data acquisition hardware and LabChart software were 
used to continuously record all physiologic parameters and EpicHeart™ Device data.   
Paired samples of 20 seconds of device standby and successive device assist were 
collected for analysis.  A data inclusion criteria of 20% ≥ CO ≥ 60% reduction from 
baseline was implemented to filter samples considered outside the targeted failure state.  
The data population over all 5 animals consisted of 62 paired samples of 20s of data (mean 
n = 29 ± 3 cardiac cycles per 20s sample).  The samples were averaged over the 20s 
selection using LabChart, and then averaged in Microsoft Excel to provide an overall 
effect for each animal.  Standard deviations are representative of variations amongst data 
runs for each animal—i.e., each run included a 20s sample of standby paired with a 20s 
sample of assist immediately following standby.  A two-tailed, paired t-test was used for 
comparison between device standby and assist for each animal, with an alpha level of 0.05 
(Excel).  
2.3. Results 
2.3.1. Deployment 
Minimally invasive deployment was successful and uneventful on the first attempt 
for four out of the five studies, and was successful on the second attempt for the remaining 
study.  In each case, EHI placement was completed without the need for cardiopulmonary 
bypass, with some brief disruption of normal cardiac electrical conduction and 
contraction.  Electrical conduction returned to normal sinus rhythm once deployment was 
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Figure 3.  Representative waveforms showing the off-pump EHI placement; (A) designates the start of deployment, (B) the end of deployment, 
(C) the timing of deployment tube removal, and (D) is the final positioning of the EHI and driveline prior to closing the chest; data sampled 
from Study 4 
 12 
 
 
Figure 4.  Changes in LVSV with device implant; the pre- and post- deployment time points were 
sampled immediately before and after deploying the EHI, and steady state samples were taken after 
closing the chest; notice that some depression occurs immediately upon implant, however recovers 
after reaching steady state in all cases 
 
 
complete.  Figure 3 is representative data demonstrating the hemodynamics during 
deployment.  EHI placement time after initial advancement to removal of deployment tube 
was on average less than 25 seconds.  Figure 2 shows the minimally invasive deployment 
process. 
With each animal, some depression of cardiac function occurred immediately 
following deployment.  Overall, the CO decreased by 0.7 ± 0.5 L/min immediately post-
deployment, however, it then recovered by 0.7 ± 1.1 L/min following chest closure and 
achievement of steady state.  Similarly, the LVSV decreased by 7 ± 6 mL, then recovered 
by 9 ± 4 mL (108% recovered).  Additionally, the MAP decreased by 16 ± 16 mmHg 
immediately post-deployment, then recovered by 12 ± 20 mmHg.  These changes in 
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hemodynamic parameters (SV and MAP) are plotted for each study in Figure 4 and Figure 
5.    
Other hemodynamic parameters showed minimal affect from EHI deployment. 
The average pulmonary artery mean pressure (PAMP) across all studies showed no change 
with deployment, and increased by 2 ± 2 mmHg once the chest was closed.   Additionally, 
the mean CVP increased by 1 ± 1 mmHg upon deployment and remained the same after 
chest closure (0 ± 2 mmHg).  Lastly, although the LV EDP showed varied effects with 
deployment, the overall change with deployment was an increase of 2 ± 1 mmHg, and an 
increase of 2 ± 4 mmHg after reaching steady state.   
 
 
 
Figure 5.  Changes in MAP with device implant; the pre- and post- deployment time points were 
sampled immediately before and after deploying the EHI, and steady state samples were taken after 
closing the chest; notice that some depression occurs immediately upon implant, however recovers 
after reaching steady state; the exception is Study 5, where procainamide was used to lower the HR 
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Table 1.  Mean Failure State Hemodynamic Data.  Summary of mean hemodynamic data during esmolol failure state for each acute ovine study; 
the sample size indicates the number of samples for the given study; each sample was 20 seconds of cardiac cycles 
 
CO SBP DBP MAP LVP CVP PASP PADP PAMP LV EDP LV SW Sample 
  L/min mmHg mmHg mmHg mmHg mmHg mmHg mmHg mmHg mmHg mmHg*mL Size 
STUDY 1 2.4 49 30 37 47 12 21 14 17 14 1110 n=13 
STUDY 2 1.8 59 38 48 49 12 21 13 16 14 1138 n=14 
STUDY 3 2.1 56 37 44 54 12 26 9 18 16 1156 n=20 
STUDY 4 2.2 47 27 35 39 17 N/A N/A N/A 12 976 n=3 
STUDY 5 1.9 56 39 47 58 12 N/A N/A N/A 19 1196 n=12 
AVERAGE 2.1 53 34 42 49 13 23 12 17 15 1115 
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2.3.2. Acute Failure Assist 
Upon activating the EHI on the failed heart, several hemodynamic parameters 
showed trends of marked improvement with systolic assist.  The failure state 
hemodynamic data prior to assist is summarized in Table 1, and the average changes with 
assist are summarized in Table 2.   In terms of recovering the healthy baseline prior to 
esmolol failure state, device assist recovered the CO by an average of 75% and the LVSW 
by 71% (mean of all 5 studies).  This recovery of baseline CO is plotted in Figure 6 for 
each study.  Figure 7 shows representative hemodynamic waveforms of device standby 
and assist during failure state.   
 
 
 
 
Figure 6.   Summary of changes in CO for each study; the Baseline data reflects the CO sampled just 
prior to inducing esmolol failure, Standby represents the mean CO during failure without device 
assist, and Assist shows the new CO during periods of device activation; the overall average recovery 
of CO was 75%. 
*p < 0.01 
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Table 2.  Changes in Mean Hemodynamics with Assist.  Summary of mean hemodynamic changes with device assist during esmolol failure for 
each acute ovine study; the sample size indicates the number of paired Standby-Assist samples of device action for the given study; each sample 
was 20 seconds of cardiac cycles 
 
∆CO ∆SBP ∆DBP ∆MAP ∆LVP ∆CVP ∆PASP ∆PADP ∆PAMP ∆LVEDP ∆LVSW Sample Assist 
  L/min mmHg mmHg mmHg mmHg mmHg mmHg mmHg mmHg mmHg mmHg*mL Size mmHg 
STUDY 1 0.8 12 3 6 14 0 2 -1 0 0 859 n=13 12 
STUDY 2 0.5 13 4 5 13 1 9 -1 2 0 680 n=14 8 
STUDY 3 0.5 12 -4 8 13 -3 13 -8 4 0 696 n=20 19 
STUDY 4 1.2 12 1 6 11 -1 N/A N/A N/A 0 764 n=3 10 
STUDY 5 0.6 14 3 7 14 0 N/A N/A N/A -2 811 n=12 16 
AVERAGE  0.7 13 1 6 13 -1 8 -3 2 0 762 
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Overall, the CO improved by 0.7 ± 0.3 L/min (+34%), SBP improved by 13 ± 1 
mmHg, and pulmonary artery systolic pressure (PASP) improved by 8 ± 5 mmHg.  
Similarly, the peak LVP improved by 13 ± 1 mmHg with systolic assist, and the LVSW 
increased by 762 ± 68 mmHg*mL (+69%).  The diastolic pressures showed a slightly 
different trend, with the overall DBP changing by only 1 ± 3 mmHg, and the pulmonary 
artery diastolic pressure (PADP) decreasing by 3 ± 3 mmHg.  The mean pressures, MAP 
and PAMP, increased by 6 ± 1 mmHg and 2 ± 2 mmHg, respectively.  Finally, regarding 
venous return pressures, the overall CVP decreased by 1 ± 1 mmHg, and the LVEDP 
remained unchanged (0 ± 1 mmHg).    
2.4. Discussion 
The EpicHeart™ Device is a non-blood contacting epicardial heart assist device 
that when activated, increases the stroke volume and offloads the heart.  Additionally, this 
technology is low-profile and is implanted successfully via minimally invasive methods.  
In this study, the EpicHeart™ Device was implanted in five animals for further assessment 
of effects in an acute failure model.  Esmolol was administered to decrease the force and 
rate of heart contractions, therefore reproducing the depressed blood pumping capacity 
seen in cases of heart failure or cardiogenic shock.  Physiologic blood pressures and CO 
were recorded during periods of short-term device standby and device assist, and were 
averaged for individual animal study device performance as well as overall trend.   
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Figure 7.  Hemodynamic waveforms sampled from each study; A, B, C, D, and E indicate Study 1, 2, 3, 4, and 5, 
respectively; the gray line shows the unassisted waveform, and the colored lines indicate the hemodynamic waveforms 
during assist 
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The repeated success of minimally invasive deployment on the first attempt shows 
significant confidence in the practical implantation of this device.  Moreover, the device 
was implanted at two different study locations with different surgical teams, further 
demonstrating the ease of use of this technology.  In the single case where minimally 
invasive deployment was not successful on the first attempt, the distal end of the EHI 
prototype was simply caught on the small pericardial access incision at the apex, 
preventing advancement from the deployment tube.  The surgeon made a slight adjustment 
to the pericardial incision, allowing for a successful minimally invasive deployment on 
the following attempt.  Given that many patients with heart failure are considered high-
risk for major surgery, a minimally invasive device placement procedure is desirable.  
Additionally, the swift deployment time – as quick as 15 seconds after access to pericardial 
sac established– opens up opportunities for other applications of this technology, such as 
in cases of acute cardiogenic shock or cardiac arrest outside of the OR.   
While the deployment process was without any major complications, there were 
two cases where an assessment of deployment on hemodynamics was more complicated.  
In the first study, dobutamine (a sympathomimetic drug that stimulates the β1 receptors) 
was administered immediately upon deployment, effectively increasing the post-
deployment hemodynamics (HR, BP, CO).  Although periodic beta-agonist drug 
intervention for maintaining normal blood pressures is common in surgical procedures, 
drug intervention was avoided in successive animal studies in attempt to narrow the cause 
of any hemodynamic changes to those that are device-related.  In studies 2, 3, and 4 the 
CO recovered by at least 83% after closing the chest.  The final study was the only case 
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to show a further reduction in the CO at steady state.  However, this animal was 
tachycardic, so procainamide was used to lower the HR; the pre-deployment HR was 120 
BPM (CO 3.9 L/min), and reduced to 84 BPM with a CO of 2.6 L/min at steady state.  For 
this reason, SV is a better indicator of changes in cardiac function with device placement.  
In previous work with this device, PV Loops were used to demonstrate that this device 
does not impede heart function.10,11  In the present study, flow probes were used in place 
of a PV Loop catheter, and once again, there was no significant difference in LVSV 
between pre-device placement and steady state post-implant.  Figure 8 shows 
representative aortic flow waveforms collected pre-deployment and at steady state post-
deployment – notice that there is almost no change in aortic flow.   
 
 
 
Figure 8.  Aortic flow before (light gray) and after EHI placement; notice that there is almost no 
change in LV SV 
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In this study, device performance was considered separately for each animal due 
to variations in healthy baseline, as well as variations in how each animal responded to 
surgery and esmolol (Figure 6).  Only the relative changes with device assist were 
considered in the overall averages, providing a clear assessment of the device (Table 2).  
Epicardial ventricular assist with this device recovered the baseline CO by at least 64%, 
with the highest at 100% recovered.  It is interesting to note the correlation between CO 
recovery and baseline; animals with a lower baseline responded better to the assist, based 
on the trend of having a higher percent recovery.  This potentially shows that the 
technology is more effective in patients with lower pumping capacity.  In the device study 
by Roche et al, a recovery of ~97% of Baseline CO was reported with ventricular assist 
when failure state was ~2.7 L/min.12  Here, if we only consider animals with a baseline of 
less than 3.0 L/min, the average recovery with EpicHeart™ assist is 97%. The trend in 
Figure 6 suggests that device performance is on the order of 0.7 L/min, and when the 
baseline is low then device assist can bring the animal back to baseline output (studies 2 
& 5), whereas when the baseline is high then device assist does not return the animal to 
baseline (studies 1 & 4).  
In addition to increasing LVSV, the device increased RVSV without impeding 
normal right-heart function.  While epicardial ventricular assist resulted in parallel 
changes in SBP, the PAMP remained 1/3 of the MAP with assist.  This indicates that 
uniform LV/RV epicardial compression did not over-assist the right heart, where lower 
pressures are the norm.  Furthermore, there were no increases in LVEDP with assist, 
indicating no increases to LV preload due to elevated pulmonary pressures.  Finally, the 
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reduced CVP and PADP both indicate that device assist offloads the heart and reduces the 
RV preload.   
2.4.1. Study Limitations 
The esmolol acute failure model, although commonly used for preclinical testing 
of similar devices, is not a true HF model.  A high dose of a beta-blocker, such as esmolol, 
is very effective in reducing the cardiac contractile strength and stroke volume.  However, 
beta-blockers do not result in the pathologic cardiac tissue growth and remodeling seen in 
many cases of heart failure.  Additionally, esmolol causes dilation of the great vessels, 
resulting in significantly reduced pulse pressures.  Therefore, the device needed to 
overcome significantly reduced pressures typically not seen in heart failure patients, which 
may have affected the recovery of cardiac output. A low preload may have limited the 
effects of epicardial ventricular assist, whereas a low afterload may have enhanced it.  The 
next stage of evaluation of this technology will include testing in an ovine model of 
chronic HF with dilated LV, providing insight on these topics left unanswered by the 
esmolol acute failure model.  
Another potential limitation is the PAP data excluded from 2 of the 5 studies.  It 
was suspected that the distal end of the Swan-Ganz catheter may contribute to pre-
ventricular contractions (PVC)s, in turn limiting device triggering and operation.  
Therefore, the transducer was retracted to no longer cross the PA valve, and consequently 
the frequency of PVCs was greatly reduced.  While the PAP data from 3 studies provides 
solid information, continued efforts will be made to assess the pulmonary pressures by 
measuring the RVP in future studies.  
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The final potential limitation to the study design is the inclusion of only 5 animals.  
Nevertheless, numerous paired standby and ventricular assist samples were collected per 
study for higher confidence in results, as opposed to collecting only representative samples 
during previous proof-of-concept studies.   To minimize bias, all samples where the device 
was properly triggered and activated, as well as met the failure state inclusion criteria, 
were included in the results reported from this study.   
The only device-related limitation of significance was the limited availability of 
prototypes, and thus it was possible for the devices to not be the ideal size for particular 
hearts.  Preliminary imaging was not completed prior to each study for device sizing; 
rather, a device was chosen from a set of up to 3 sizes, based on intraoperative fluoroscopic 
imaging and by recommendation of the lead surgeon.  While the passive component of the 
EHI device has significant volume, and can be adjusted for variations in circumferential 
dimension, substantially larger hearts were more difficult to accommodate.  This was 
apparent in study 2, where the heart was unexpectedly large in the axial dimension, and 
only one size of the EHI prototype was available; this animal experienced the most 
significant decrease in SV and increase in CVP immediately upon deployment.  However, 
since the SV recovered to 85% of the pre-deployment level, and CVP remained within a 
physiologic range, the procedure was continued.   An additional indicator of a potentially 
undersized device was the LVEDP.  In study 2, the LVEDP increased slightly upon 
deployment, and instead of reducing upon chest closure, this LV filling pressure continued 
to rise.  A similar situation occurred in study 4, which also reflected the changes in SV 
and CVP reported for deployment in study 2.  In study 5, however, the LVEDP remained 
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unchanged with device placement, in combination with almost no change in SV, likely 
indicating an ideal fit.  By study 5, additional sizes of the EHI prototype were available 
for the procedure.  Future studies will incorporate a wider range of available device sizes.  
2.5. Conclusion 
Results of the current study show the efficacy of the EpicHeart™ Device to assist 
the failing heart acutely.  Minimally invasive surgical implantation was a repeated success, 
combined with significant recovery of cardiac hemodynamics with device assist during 
acute failure.  The next phase in developing this technology will include longer-term 
implantation, and a pilot investigation of the EpicHeart™ in a chronic heart failure model 
with dilated growth and remodeling.  
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3. SIMULATION OF EPICHEART™ EFFICACY 
3.1. Introduction 
There has been a growing need for simulation tools in research.  By developing 
robust simulation methods, researchers can better plan for in vivo studies, ideally allowing 
for a reduction in the total number of subjects necessary for exploring the study aims.  
Additionally, simulation allows for better planning when transitioning from acute studies 
to chronic studies.  In regards to investigating the preclinical efficacy of the EpicHeart™ 
Device, a direct cardiac compression (DCC) device with novel features that enable less 
invasive implantation and more physiological cardiac deformation, several unknowns will 
remain after the acute failure model studies have concluded.  Specifically, it remains to be 
seen how a subject with normal to elevated hemodynamic pressures or a pathologically 
remodeled heart will respond to this DCC, as this morphology is absent in the acute models 
but is characteristic of many clinical cases of heart failure.     
To this end, a modified Harvi iPad application with the capability to simulate 
EpicHeart™ function in a clinical model is in the early stages of development.  This new 
application builds on the existing Harvi simulation tool – a real-time, interactive 
simulation of the cardiovascular system used for exploring basic hemodynamic principles 
in health and disease, and for predicting the effects of device- and surgical-based 
treatments for heart failure.   The Harvi app has been used by other groups for clinical 
simulation, with examples that include patient selection for mechanical circulatory 
treatment,16 prediction of the effects of an interatrial shunt for patients with elevated 
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PCWP,17 and prediction of the hemodynamic effects of varying degrees of right 
ventricular support in patients with pulmonary arterial hypertension.18  
Although the indication for the technology has yet to be specified, the benefit of 
such a simulation tool to DCC device design and development as well as future clinical 
use is substantial.  The next step in the design process for this simulation tool is to verify 
the performance specifications.  The simulation tool presently includes customizable 
EpicHeart™ inputs with simulated physiologic outputs.  To this end, the present study 
reports the results of a pilot study of simulating device action compared with in vivo data 
of device action.   
3.2. Materials and Methods 
3.2.1. Device Assist Simulation Controls 
The DCC device was simulated using the parameters listed in Table 3.  All data 
simulated was during assist once every cardiac cycle, or a Ratio of 1:1. The Offset is the 
device pressure during diastole, and is intended to model any passive restraint on a dilated 
heart.  Since the data modeled here is an acute heart failure model, this parameter was not 
evaluated in this study; the value was 0 mmHg for all simulations.  The Delay is intended 
to model any time delay between the start of IVC and the start of inflation of the device.  
There was no delay in the selected data for this simulation study, and therefore the value 
for this input was 0 ms.  The “Trigger to Assist Delay” feature in the Driver user interface 
is a time delay from the QRS trigger to the start of IVC.  Since the model defaults to 
initiating assist with the start of IVC, there is no need for a delay in this simulation.   
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Table 3.  List of Inputs for Device Simulation 
INPUT UNIT DESCRIPTION 
Ratio BPM: n Ratio of assist cycles to cardiac cycles 
Offset mmHg Device pressure during diastole 
Delay  ms Time delay of inflation from start of LV contraction 
Rise mmHg/ms Rate of pressure rise 
Amplitude mmHg Pressure during full inflation 
Decline mmHg/ms Rate of pressure decline 
Duration ms Duration of pressure pulse 
 
 
The current simulation design involves a trapezoidal pressurization waveform with 
a linear inflation rate, a stable peak pressure, and a linear deflation rate.  The device assist 
pressure was collected using a Millar Mikro-Tip® Catheter Pressure Transducer (Model 
SPR-320, Size 2F) placed in a fluid chamber (the passive component) located between the 
active compressive assist component of the Implantable and the surface of the heart.  This 
transducer was used to record the instantaneous pressure applied by the device to the 
outside of the heart.  
The goal of this investigation was to simulate systolic assist; therefore, only the 
systolic components of the device pressure waveform were included in the average  
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Figure 9.  Instantaneous device assist pressure, measured by floating a Millar in the fluid of the passive 
chambers, providing a metric of epicardial assist 
 
 
pressure calculations.  Since passive pressure is not constant during assist (Figure 9), and 
fluctuates between inflate and deflate with systole and diastole, the Amplitude was 
approximated using an average weighted with systole: 
 <x(t)> = 
∫ ω(t)*x(t)dt
tf
ti
∫ ω(t)dt
tf
ti
 ( 1 ) 
where ω(t) is the weight function.  To create the weight function, we used the LVP, mean 
LVP (<LVP>), and the signum function: 
 sgn(x) = {
 0 if x≤0
 1 if x>0
   ( 2 ) 
The first step was to subtract the mean LVP from the original LVP channel.  Then, we 
calculated the signum (Eq. 2) of the resulting signal to get the weight function ω(t): 
 ω(t) = sgn(LVP - <LVP>)  ( 3 ) 
To find the systolic components of the assist pressure channel, we multiplied: 
 ω(t)*p(t)  ( 4 ) 
Then we applied Eq. 1 to find the average device pressure, <p(t)>, weighted with systole: 
 <p(t)> = 
 ∫ ω(t)*p(t)dt 
tf
ti
∫ ω(t)dt
tf
ti
   ( 5 ) 
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This provided an assist pressure averaged over the systolic period, and excluded 
any diastolic components.  To mitigate any potential inaccuracies in calibration of the 
transducer – due to temperature variation between room temperature and body 
temperature – the relative pressure was calculated by taking the systolic weighted average 
pressure during assist, and subtracting off the systolic weighted average pressure during 
the preceding sample of standby data. 
The Rise and Decline of assist were determined based on the average slopes of the 
device pressure signal.  These were determined using LabChart software, by taking the 
instantaneous derivative of the device pressure signal and multiplying by the systolic 
weight function (Eq. 3) to create two new signals, one with only positive instantaneous 
derivatives, and one with only negative instantaneous derivatives: 
 Rise = ω(t)* [
dp(t)
dt
 + |
dp(t)
dt
|
2
]  ( 6 ) 
 Decline= ω(t)* [
dp(t)
dt
 - |
dp(t)
dt
|
2
]  ( 7 ) 
The instantaneous slopes are plotted with the passive pressure, p(t), in Figure 10.  
The cyclic maxima and minima of these positive and negative slopes were averaged to 
determine the Rise and Decline rates of pressure (inflation and deflation rates). The result 
was a slope in mmHg/s, which was rounded to the nearest 0.2 mmHg/ms to accommodate 
the model units. 
Finally, the Duration of assist was simulated using the average time duration of 
each systolic weight function cycle: 
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Figure 10. LabChart channels displaying the passive pressure, p(t), and the instantaneous derivatives 
for positive and negative slopes 
 
 
 Duration =
 ∫ ω(t)dt
tf
ti
n
  ( 8 ) 
Where n is the number of cardiac cycles in the data sampled from ti to tf.  Figure 11 shows 
the simulated assist pressure plotted with the in vivo assist pressure.   
3.2.2. In vivo Data Source 
All hemodynamic pressures were recorded using either a Millar solid-state pressure 
transducer or a fluid-filled catheter.  The CO from all studies was acquired using a 
Transonic COnfidence flow probe, placed on the ascending aorta.  The source of 
hemodynamic data is described in Section 4.2.    One key difference was where this study 
cited a sample inclusion criteria based on the CO relative to pre-failure baseline, all  
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Figure 11.  Assist pressure waveforms, comparison of in vivo to simulation 
 
 
samples were included in this simulation study to maximize the sample population for the 
best possible assessment of model performance.   
One parameter that was not measured in these in vivo studies was the PCWP.  
However, as this parameter is often used as an approximation of the LV EDP, which was 
measured using a solid-state pressure transducer (Millar) placed in the LV, the LV EDP 
data was used to approximate the PCWP.  Additionally, there were two studies where PAP 
was missing; during these studies, it was suspected that the source of recurrent pre-
ventricular contractions (PVCs) was the Swan-Ganz transducer for PAP, and thus the 
catheter was retracted to no longer cross the PA valve.  Therefore, the PAP inputs were 
approximated for these two studies, using the LV EDP as the PA diastolic pressure, and 
 32 
 
applying a 10 mmHg PA pulse pressure.  This was based on the average PA pulse pressure 
during acute heart failure in the two studies where the PAP was measured in vivo.  
Cardiac chamber volume and ventricular wall thickness were approximated based 
on a sample of CT dimensions acquired during a previous scan of an anesthetized ovine.  
As this was an acute HF study with no pathologic growth and remodeling, the cardiac 
geometry was held constant for all simulations.  Additionally, data analysis focused on the 
relative change in hemodynamic parameters, and thus results were expected to be 
minimally impacted by not using exact cardiac geometries.  In place of using the cardiac 
volumes from the CT to calculate EF, this parameter was calculated for the simulation 
using the SV – defined by CO/HR – from each sample, and only the LV EDV from the 
CT.  On a similar topic, the LVSW was not calculated using volume data.  SW is most 
commonly found as the area within a PV Loop, however since ventricular volume was not 
measured in vivo, an alternate method was applied.  Knowing that power, P(t), in a fluid 
system can be found using the following equation: 
 P(t) = p(t)*Q(t)  ( 9 ) 
Left-heart power could be calculated using the LVP and Ao flow.  This data was 
then converted from mmHg*mL/s to Watts for assessment of the simulated LV CPO.  
Finally, knowing that work is the integral of power, we found LVSW by taking 
the integral of the instantaneous power channel, and dividing by the number of cycles n in 
the sample from ti to tf:    
 LVSW = 
∫ P(t)dt
tf
ti
n
  ( 10 ) 
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3.2.3. Evaluation of the Simulation 
The in vivo hemodynamic data during device standby provided the inputs for the 
“Patient Simulator” feature of the application to establish the simulated patient baseline 
(summarized in Table A 1).  Then, the “CorInnova Device” feature was turned on, using 
the process described above to determine the inputs (summarized in Table 3).  The steady 
state hemodynamic outputs under the simulated assist conditions were compared to the in 
vivo hemodynamic data during assist conditions.  Only certain hemodynamic outputs were 
included in this pilot investigation, based on the availability of in vivo data for verification 
(summarized in Table A 2).  To normalize the data, the relative change in each parameter 
from Standby to Assist – denoted as the Delta value – was compared between simulation 
and in vivo.   
 ∆ = Assist - Standby   ( 11 ) 
The Delta values were averaged for each animal study, to reveal any differing 
results due to study conditions.  Standard deviations reflect variation in data between 
paired samples for the same study.  Finally, due to differing sample sizes per animal study, 
these mean Delta values from each animal were averaged together (n=4) to provide an 
overall assessment of simulation accuracy, weighted equally for each animal study.  
Standard deviations here reflect variation in overall performance between each animal 
study.  
As a metric to compare the simulation to the in vivo data, we calculated an 
expectation percent, defined as: 
 % expectation= 
∆ in vivo  
∆ simulation
  ( 12 ) 
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The simulation was chosen as the expectation, as the model assumes no energy 
lost between epicardial compression and ventricular assistance, and thus will simulate 
Delta values as anticipated.  A metric above 100% would indicate that the device 
performed above expectations, where below 100% would indicate that the device provided 
cardiac assistance to the patient below expectations.  This was a blinded study, where the 
simulation operator was provided with only the hemodynamic data during in vivo device 
standby, and the proper device settings for that paired sample, and an analyst compared 
the results of simulated device assist to the hemodynamic data during in vivo device assist.   
3.3. Results 
3.3.1. Individual Study Simulation Performance 
The results of the delta values for each hemodynamic parameter are summarized in Table 
4 for comparison between simulation and in vivo, as well as Figure 12 and Figure 13.  See 
Figure A 1 and Figure A 2 for hemodynamic waveform comparison between in vivo and 
in silico.  Individual study analysis revealed Study 2 to be an outlier.   The changes in 
systemic pressures (SBP, DBP, MAP) as well as pump function (SV, CO, LVSW, 
LVCPO) with device assist were consistently lower in vivo than the simulated 
hemodynamic outcomes.  In contrast, these parameters showed paralleled results in the 
simulation and in vivo for the remaining three studies.   
The change in LVEDP predicted by the simulation was mostly opposite to the 
trend in vivo; where the model predicted an increase in LVEDP with device assist, the 
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results in vivo were generally unchanged.  Similarly, the model consistently predicted an 
increase in DBP and PADP, where these parameters mostly decreased with assist in vivo.   
Finally, there was a correlation between EHDP and SBP, especially in Study 1 and 
Study 4 where the increase in SBP was equivalent to the EHDP.    
3.3.2. Overall Simulation Performance 
After assessing the model for each individual animal study, the hemodynamic 
parameters of interest were averaged over the four in vivo sample sets, to compare in vivo 
to in silico overall.  Beginning with the systemic changes, the in vivo SBP and MAP values 
increased by 11 ± 1 and 7 ± 1 mmHg with assist, compared to 12 ± 4 and 9 ± 4 mmHg 
predicted by the model.  In contrast, the in vivo DBP showed a trend opposite to that of 
the simulation; the simulation predicted an average increase in DBP of 7 ± 3 mmHg, when 
the average change in DBP was actually a decrease of 1 ± 3 mmHg.  Finally, both the in 
vivo CVP and the predicted CVP showed a slight decrease in pressure with device assist; 
the model predicted an overall decrease in CVP of 2 ± 1 mmHg, while the overall effect 
in vivo was a decrease of 1 ± 2 mmHg.   
The changes in pulmonary pressures showed a similar trend as the aortic blood 
pressures; the in vivo mean PAP increased by only 4 ± 4 mmHg with assist compared to 7 
± 3 mmHg in silico, and the systolic PAP increased by 8 ± 7 mmHg in vivo compared to 
7 ± 3 mmHg in silico.  Moreover, the diastolic PAP decreased by 5 ± 6 mmHg in vivo but 
increased by 6 ± 3 mmHg in silico; the trend in diastolic PAP was consistent with the trend 
in Aortic DBP.  Finally, there was no change in LV EDP in vivo (0 ± 1 mmHg), however 
the model predicted a 5 ± 3 mmHg increase in LV EDP with assist.  
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Table 4.  Summary of changes in hemodynamic outputs, comparison of simulation and in vivo 
  STUDY 1 ∆ STUDY 2 ∆ STUDY 3 ∆ STUDY 4 ∆ 
  Simulation In Vivo Simulation In Vivo Simulation In Vivo Simulation In Vivo 
SBP (mmHg) 11 11 18 12 8 12 10 9 
DBP (mmHg) 6 3 11 -3 4 0 7 -2 
MAP (mmHg) 8 7 15 9 6 7 8 6 
PASP (mmHg) 7 3 12 13 5 N/A 5 N/A 
PADP (mmHg) 5 -1 10 -9 2 N/A 5 N/A 
PAMP (mmHg) 6 1 11 6 4 N/A 5 N/A 
CVP (mmHg) -2 0 -4 -3 -1 -1 -2 1 
LV EDP (mmHg) 5 0 9 1 2 0 4 -1 
LV SV (mL) 11 9 14 5 11 14 6 4 
CO (L/min) 1 0.9 1.3 0.5 0.9 1.2 0.5 0.4 
LV SW (mmHg*mL) 492 828 764 683 535 764 415 580 
LV CPO (Watts) 0.13 0.17 0.23 0.14 0.11 0.14 0.12 0.12 
EHDP (mmHg) 11 11 19 19 9 9 9 9 
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Figure 12.  Changes in MAP (A), LV EDP (B), PAMP (C), and CVP (D) with device assist, in vivo and simulated 
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Figure 13.  Changes in LVSV (A), LVSW (B), CO (C), and LVCPO (D) with device assist, in vivo and simulated  
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When evaluating the pump function of the heart in vivo, the LV SV and LV CO 
were 73% and 89% of the expected change in output.  The LV CO increased by 0.8 ± 0.4 
L/min with assist in vivo, and increased by 0.9 ± 0.3 L/min in silico.  The LV SV increased 
by 8 ± 5 mL in vivo, and increased by 11 ± 3 mL in silico.  Additionally, the LV SW was 
129% of the expected results.  This was the only cardiac pump function metric to exceed 
the expectations of the simulation (when considering model performance over all animal 
studies).  Finally, the LV CPO was 93% of the simulated results, with an increase in vivo 
of 0.14 ± 0.02 Watts compared to an increase of 0.15 ± 0.06 Watts in silico.  
3.4. Discussion 
This study was a pilot investigation of a new application of the Harvi 
cardiovascular simulation program.  This version of the Harvi platform builds on the 
existing iPad program, developed using the Burkhoff model of the cardiovascular system, 
with the added feature of the ability to simulate the effects of the EpicHeart™ Device.  In 
developing this technology, the performance specifications needed to be verified.  Thus, 
in vivo data from 4 acute ovine studies was used to simulate device standby conditions as 
well as assist conditions.  The resulting effects on the cardiovascular system in silico and 
in vivo were compared by evaluating the absolute changes, as well as considering the 
model results as the expected outcome and the in vivo results as a percent of that 
expectation for certain parameters. 
Perhaps the most unexpected result of this study was the change in LV EDP.  The 
simulation data for each parameter defined the expected outcome.  However, the LV EDP 
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was the only parameter to predict a trend with assist that was not anticipated by our group; 
the simulation resulted in an average increase in LV EDP of 5 ± 3 mmHg – in direct 
contrast to the anticipated decrease in LV EDP.  It has been shown that mechanical heart 
assist will offload the heart, resulting in a decreased preload to the LV.  This is usually 
observed by a measured reduction in LV EDP (effectively LAP).  When the device was 
tested in vivo, there was 0 ± 1 mmHg change in mean LV EDP with assist.  An average of 
no change with a standard deviation of 1 mmHg does not reveal a clear trend in vivo.  
However, the in vivo data was from acute studies, where cardiac decompression was not 
anticipated with short-term assist.   
One potential explanation for the simulated increase in LV EDP is that it is a 
previously unknown consequence of biventricular assist with this device.  During device 
operation, the goal is to maximize the epicardial systolic assist pressure.  Although the 
ideal assist pressure is currently not defined, the Driver operator maintains the assist 
pressure within a reasonable range – typically below 30 mmHg.  While maximizing the 
assist pressure reflects positive results in the increased output of the heart, it is possible 
that maximized assist pressures could have an adverse effect on the right-sided pressures.  
Specifically, it is possible that if the PAP was too high as a result of uniform RV/LV assist, 
the downstream LA pressures and LV EDP would be increased as well.  If the pulmonary 
pressures are abnormally high, the likely in vivo or clinical outcome would be pulmonary 
edema.    However, it is expected that auto-regulatory mechanisms will be stimulated by 
the biventricular assist, which should balance the increased pulmonary pressures.   
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Another possible explanation for the differing effect on LV EDP is that the model 
needs a proportional distribution of the effects of epicardial assist between the left and 
right side of the heart.  The simulation predicted a decrease in CVP with a significant 
increase in LVEDP, where the in vivo results show a slight decrease in CVP, and almost 
no change in LVEDP.  Additionally, the ratio of EHDP (EpicHeart Device Pressure) to 
LV ESPVR shift in slope appears to be 1:1 in vivo and in the simulation; however, the 
data from Study 1 – chosen for optimal device fit and presence of in vivo PAP data – 
reveals a smaller shift in the RV ESPVR with assist than predicted by the simulation.  
Given the differing RV ESPVR shift in silico compared to in vivo, combined with the 
significant predicted increase in LVEDP, it is possible that the model overestimates the 
effect on the right side of the heart.  Further studies are needed to explore this theory.    
3.4.1. Pump Function Expectations  
The LV CO, LV SW, and LV CPO all increased in vivo with device assist, 
reflecting the anticipated changes in cardiac pump function.  While the overall change in 
LV SV was only 73% of the expected outcome, the overall average LV SW exceeded 
expectations at 129%.  This can be explained by the difference in method for calculating 
LV Power and LV SW.  
The integral method overestimates the loop area because it includes the area under 
the EDPVR curve.  Moreover, since the model predicted an increase in LVEDP, the 
EDPVR curve was shifted upward, further removing the in vivo LVSW from the predicted 
LVSW.  While our method is a calculation of true work in a fluid system, and was used 
due to the absence of a volume transducer, it is not consistent with the model method.  
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Thus, efforts should be made to use a PV Loop transducer in future studies, permitting 
calculations of SW to be consistent with the clinical method of the area inside a PV Loop 
plot.   
3.4.2. Simulation Outliers 
The results of the individual animal studies suggest that Study 2 is an outlier.  The 
predicted hemodynamic effects of device assist in this study were the most removed from 
the in vivo effects, compared to the other three studies.  During this particular animal study, 
it was determined by observation of the lead surgeon and confirmed by fluoroscopic 
imaging that the EpicHeart™ prototype implanted was significantly undersized for the 
heart.  This particular heart geometry was unusually long in the axial dimension; thus, the 
prototype was determined to be too small in the axial dimension.  Figure 14 demonstrates 
the difference between an optimally sized device, and the fit observed in Study 2.  Even 
with a relatively high EHDP, the increase in CO was only 38% of the expected change, as 
determined by the model (Figure 13).  Additionally, it is interesting to note that the 
increase in transmural pressure no longer reflects the device pressure when the device is 
too short (as determined by the ∆SBP); the average EDHP in Study 2 was 19 mmHg, 
however the ∆SBP was only 12 mmHg.  Other studies show at least a 1:1 relationship 
between the EDHP and the ∆SBP.  The outlier results of this study due to a poorly sized 
device provide insight for the design of DCC devices, and have clinical implications for 
the effect of implanting an incorrectly sized DCC device.   
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Figure 14. Fluoroscopic image comparison of Study 2 (A) and Study 5 (B); notice the abnormal 
geometry of the heart in A compared to B 
 
 
 
3.4.3. Study Limitations 
Certain limitations in this study have already been discussed, namely the 
deviations from the clinical/model method for calculating the SV, SW, and CPO.  One 
other potential limiting factor here was the estimation method for PAP when that 
parameter was not measured in vivo.  The Swan-Ganz catheter used to measure the PAP 
was retracted from the PA during certain animal trials, as it was suspected to be the cause 
of recurrent arrhythmias.  Thus, the systolic and diastolic PA pressures were estimated 
based on the LV EDP and an average PA pulse pressure during failure of 10 mmHg.  It is 
possible that the pulse pressure was underestimated, and in turn underestimating the 
systolic PAP used for simulation.  Thus, this could potentially be the source of the in vivo 
results exceeding the expectations of the model for this parameter.   
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Additionally, we acknowledge that certain parameters measured in vivo were 
beyond the practical limitations of the Patient Simulator feature in the model.  Specifically, 
the lower limit for the PADP input was 10 mmHg, however certain samples of in vivo data 
were actually lower than 10 mmHg, and thus these samples were approximated to 10 
mmHg.  Similarly, the lower limit for the Rise input of device simulation was 0.2 
mmHg/ms, however in some in vivo samples, the Rise was as low as 0.1 mmHg/ms.   
Next, there was a variation in the number of samples from each in vivo study – 
least at n = 3, to most at n = 36.  Delta values were used to normalize any variation in 
baseline between animals, and all Deltas for each parameter were averaged over the 
sample set for each animal study.  Then the individual study averages were subsequently 
averaged overall in order to provide equal weight for each study.  Thus, any inexactitudes 
due to limited samples from an individual animal should be inconsequential.  
An additional limitation was the method for simulating device assist.  The 
epicardial systolic assist pressure waveform is modeled as a trapezoid with a linear 
pressurization, a constant peak pressure, and a linear depressurization.  While this is a 
reasonable approximation for the pressurization waveform of the normal LVP, the device 
systolic assist pressure has some variation in vivo, partially due to each animal’s unique 
response to the device.  Moreover, the majority of this variation is likely due to exploration 
of the optimal assist pressurization during each proof-of-concept study and further 
development of the driver.  However, as the model predicts the optimal results, this 
information reveals that an epicardial assist pressurization that more closely resembles the 
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trapezoid shape is perhaps desirable, and might be considered as a design specification to 
target when optimizing the driver.   
While initially focusing on hemodynamic data was a valid starting point for 
simulation verification, we acknowledge that certain Harvi parameters were excluded 
from assessment in this study.  Most notably, the cardiac geometry data – volume, ejection 
fraction, and wall thickness – was not verified in this analysis.  Accurate cardiac geometry 
measurements from high-quality imaging (CT or MR) were beyond the scope of these 
acute failure studies.  While a single ovine CT scan was available for use in estimating the 
baseline ventricular volumes and wall thicknesses, this information was not used to verify 
the volume simulation parameters.  However, it is unlikely that this information was 
detrimental to the validity of the results of this study, as minimal change in cardiac volume 
is expected with the esmolol acute failure model since these are animals with no cardiac 
remodeling.  Additionally, the baseline volumes were held constant for all simulations, 
normalizing any effect on hemodynamic performance specification assessment due to 
cardiac geometry.  Finally, the MVO2 hemodynamic output was excluded from 
verification due to the absence of this data from all acute animal studies.  It is currently 
unknown how the device under investigation in this study affects this parameter when 
implanted and activated.     
3.5. Conclusion 
This study described the results of a pilot simulation study of the EpicHeart™ 
Device – a DCC device with novel features that enable less invasive implantation and 
 46 
 
more physiological cardiac deformation with systolic assist.  Overall, the results of the 
comparison between in vivo and in silico were quite similar, indicating the technical 
specifications of the model require limited modifications for simulating this DCC device 
in an acute heart failure model.  Future studies will include additional acute HF model 
verification, along with chronic HF model verification using echo data for assessment of 
the cardiac geometry parameters.   
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4. DEVELOPMENT OF A PNEUMATIC DRIVER FOR DCC DEVICES TO 
MIMIC INNATE CARDIAC VENTRICULAR PRESSURIZATION AND 
HEMODYNAMICS 
4.1. Introduction 
As significant effort has been devoted to optimization of the EpicHeart™ 
Implantable (EHI), a fully-developed pneumatic driver system is likewise important to 
optimum heart assist.  Currently, it is unclear what driver pressurization (i.e. timing and 
magnitude of pressure applied) will result in the greatest increase in stroke volume; limited 
data on this subject has resulted from preliminary studies.  In addition to the likelihood of 
suboptimal hemodynamics, inappropriate timing of pressurization may be detrimental to 
healthy cardiac tissue.  Specifically, if the pressurization rate, duration, or timing of onset 
is too late in systole, the EHI may still be pressurized during isovolumetric relaxation 
(IVR), in which case the device may restrict rapid filling in early diastole.  In contrast, if 
the EHI is pressurized prematurely, transmural pressure may be applied prior to papillary 
contraction – resulting in possible regurgitation through the AV valves due to 
compromised valve coaptation or interruption of atrial systole.  Over an extended period 
of time, this improper timing of transmural assist may lead to papillary tissue damage.  
Clearly, pressurization onset time, rate, duration, and waveform morphology are vital to 
heart assist, and will be further explored in this study. 
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4.2. Methods 
Three unique versions of the EpicHeart™ Driver were investigated in this study.  
A description of the control parameters and components of each version is detailed in the 
following sections. 
4.2.1. Parameters to Adjust for Heart Synchrony 
While the electrical-pneumatic delay in the Driver is minimal (~15ms, see Figure 
15), there is a native electrical-mechanical delay in the normal heart.  Therefore, one of 
the parameters used for synchronization between Driver function and heart function was 
the Trigger to Assist Delay (TAD).  Figure 16 explains the basis of this parameter, 
demonstrating the time between ECG Trigger and the end of atrial systole.  As the 
physiologic electrical-mechanical delay varies between subjects and contractile state, this 
parameter was a manual user input to be adjusted as needed during in vivo testing.  The 
measured time between the ECG Trigger (coinciding with the peak of the R wave) and the 
start of cardiac isovolumetric contraction (IVC) during device standby quantified the 
minimum value for TAD.  Proper synchronization with heart function was verified by 
overlaying the device passive pressure waveform and the left ventricular pressure 
waveform to visually check for synchronization between EHI pressurization and IVC.  
After defining the timing of optimal initiation of assist, the user determined the 
Inflate Duration (ID).  This user-defined time parameter specified how long the Inflate 
solenoid valve was open to the Driveline, and thus the EHI (see Figure 17 for the Inflate 
valve).  Together, the TAD and ID determined the Assist Duration (AD), defined as the 
time from the ECG Trigger to Inflate valve closure. The AD was adjusted within the limits  
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Figure 15. Waveform demonstration of the electro-pneumatic delay in the driver; notice the QRS 
peak and the ECG trigger are almost coincident, with only a 15ms delay from ECG trigger to the start 
of passive chamber pressurization 
 
 
 
 
Figure 16.  Waveform demonstration of the need for a Trigger to Assist Delay (TAD); notice the 
significant delay of 35ms from the trigger to the end of atrial systole 
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of the software, and in a method such that the maximum increase in cardiac SV was 
achieved without compromising the EHI chamber integrity.   
Finally, in connection with the timing of solenoid valve activation, it was possible 
to modify the rate of pressurization of the EHI.  The rate of pressurization was adjusted 
such that the maximum stroke volume could be achieved.  It was unknown if a rapid 
pressurization rate or a slower rate would yield the greatest stroke volume, hence both 
conditions were explored.  The pressurization rate was modified by adjusting the reservoir 
pressure, and/or by modifying the pneumatic driveline (i.e. pneumatic capacitor).   
4.2.2. Driver V1: Parallel Pneumatic Disks, Regular Driveline 
This generation of the driver includes updated hardware featuring additional 
solenoid valves as well as pneumatic isolator disks (safety disks) which mechanically 
isolate the EHI from the pressure reservoir.  This limits the amount of volume available 
for infusion into the EHI for each inflate cycle, and the EHI is vented to atmosphere 
following each inflation cycle. This method of volume delivery limits the available 
pneumatic stroke volume, while providing a safety mechanism which mitigates the 
potential for device over-inflation.  Additionally, each solenoid valve is individually 
controlled with unique valve states for highly customizable assist.  The pneumatic 
hardware for the Parallel Driver is summarized schematically in Figure 17.  
4.2.3. Driver V2: Parallel Pneumatic Disks, Pneumatic Capacitor Driveline   
This version of the Driver has the same hardware setup as V1, however includes a 
pneumatic capacitor in line with the driveline to attenuate the pressurization spike seen 
within the chambers of the EHI with a regular driveline, while extending the pulse width 
 51 
 
 
Figure 17.  Pneumatic hardware schematic of the Parallel Disk driver; P1-6 are pressure transducers; each solenoid valve is labeled by name, 
Pressure, Vent, Vacuum, Refill, Inflate, Equalize, and Deflate; the ISO IN and ISO OUT label the input and output side of the pneumatic isolators; 
EHI labels the output of the driveline to the EpicHeart™ Implantable 
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Figure 18.  Schematic drawings of the pneumatic capacitor
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of the pressurization waveform.  Figure 18 illustrates the pneumatic capacitor with 
engineering drawings.  The pneumatic capacitor consisted of a rigid cylinder of adjustable 
volume with a dome cap supporting a flexible membrane.  This membrane allowed air to 
collect and eject during each inflation cycle, thus attenuating the rapid initial 
pressurization of the EHI seen with the regular driveline.  The capacitor permitted a 
slightly longer ID (effectively AD) due to the slower inflation rate, in addition to a higher 
tank pressure; an extended AD was the priority here to examine the effect of longer assist.    
4.2.4. Driver V3: Series Activation of Pneumatic Disks 
The Series Driver featured pneumatic isolator disks designed to activate in series 
– in contrast to V1 with 3 pneumatic isolator disks that activate in parallel.  Two separate 
Driver control computers allowed each pneumatic isolator disk stage to be activated 
independently.  To facilitate synchronized triggering, the trigger signal from the IVY 7700 
Patient Monitor was bifurcated to two separate Driver circuit board configurations.  One 
set of electrical controls (Driver 1) controlled a single pneumatic isolator intended to 
activate during IVC, and the other set of electrical controls (Driver 2) were dedicated to a 
pair of pneumatic isolators coupled in parallel, designed to activate during the ejection 
phase of systole. 
Both drivers in this system shared the same Isolator Input space, controlled by a 
single Pressure valve, a single Vacuum valve, and a single Vent valve.  Each driver in the 
system had its own Inflate, Refill, Deflate, and Equalize valves; however, the only valves 
that did not open in synchrony were the Inflate valves. The inflate valves did, however, 
close in synchrony so long as both driver Assist Durations (TAD + ID) were equal.  The 
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activation timing of each stage (TAD1 and TAD2) is illustrated in Figure 19 and the 
pneumatic hardware setup for this Driver is summarized schematically in Figure 20. 
4.2.5. In vivo Study Methods 
Two (2) separate acute ovine, non-GLP studies were conducted for this 
investigation.  Each study utilized a single, anesthetized adult domestic cross ovine (62-
78 kg).  The in vivo study methods, including surgical approach, device implantation, and 
acute failure model for this investigation are identical to those described in Section 4.2.2.    
All experiments were conducted under an Animal Use Protocol (AUP) that was approved 
by the Texas A&M University Institutional Animal Care and Use Committee (IACUC) or 
the Texas Heart Institute IACUC.  
4.2.6. Data Collection and Statistical Analysis 
ADInstruments PowerLab data acquisition hardware and LabChart software were 
used to continuously record all physiologic parameters and EpicHeart™ data.   All 
physiological pressures and flows were obtained using the methods described in Section 
4.2.2.  Paired samples of 10-20 seconds of device standby and successive device assist 
were collected for analysis.  The data population over 2 animals consisted of 10 paired 
samples of 10-20s of data.  The samples were averaged over the selection using LabChart, 
and then averaged in Microsoft Excel to provide overall results for each Driver version.  
Standard deviations are representative of variations amongst data runs for each animal. 
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Figure 19.  Waveform demonstration of the TAD1 and TAD2 parameters for the Series Driver (V3) 
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Figure 20.  Pneumatic hardware schematic of the Series Driver; P1-6 are pressure transducers; each solenoid valve is labeled by name, Pressure, 
Vent, Vacuum, Refill, Inflate, Equalize, and Deflate; the ISO IN and ISO OUT label the input and output side of the pneumatic isolator disks; 
STAGE 1 was activated with cardiac IVC and was controlled by one computer, while STAGE 2 was activated during cardiac ejection and was 
controlled by a second computer 
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4.3. Results 
4.3.1. Regular vs. Capacitor Driveline, Acute Failure 
When the driveline pneumatic capacitor was included with Driver operation, there 
was some improvement to device assist.  The Driver with the regular driveline could not 
operate with an assist duration above 125 ms and a reservoir pressure of 100 mmHg 
without compromising Implantable prototype integrity.  However, the Driver with the 
pneumatic capacitor in the driveline permitted a slightly longer assist duration of 150 ms, 
and a higher reservoir pressure of 150 mmHg.  Additionally, the average systolic assist 
pressure with the regular driveline was only 19 mmHg, but increased to 23 mmHg with 
the higher reservoir pressure used for the pneumatic capacitor driveline.    
This application of increased epicardial assist during acute esmolol-induced failure 
conditions resulted in some improvement to cardiac pump function hemodynamics 
(Figure 21).  Assist with the regular driveline resulted in a 0.8 L/min improvement in CO, 
however assist with the pneumatic capacitor resulted in a 1.1 L/min increase in CO.  
Similarly, the increase in SV improved with the inclusion of the pneumatic capacitor – a 
14 mL increase versus only a 10 mL increase in SV.  Additionally, the increase in LVSW 
with the regular driveline was 113%, and was even better at 163% with the pneumatic 
capacitor driveline.   
The majority of the hemodynamic pressures – specifically SBP, PASP, PADP, and 
PAMP – resulted in similar changes with both versions of the Parallel Driver (Figure 22).   
However, there were differing effects on the MAP and DBP between the two versions of 
the Driver; while the DBP increased by 3 mmHg with the regular driveline, it actually 
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decreased by 6 mmHg with the capacitor driveline, resulting in a lower MAP during assist. 
Finally, assist with both Drivers lead to an increase in the mean CVP.  This change was 
much greater with the capacitor driveline, an increase of 5 mmHg versus an increase of 
only 1 mmHg.   
Assist during acute esmolol-induced failure with each version of the pneumatic 
driveline resulted in mostly comparable hemodynamic waveforms (Figure 23).  One slight 
difference was the transition between the Inflate Duration and the closing of the Inflate 
solenoid valve.  Assist with the capacitor driveline had a smoother transition when the 
Inflate solenoid valve closed, opposed to the abrupt change with the regular driveline.  
Notice that the LVP and AoP experience a slight decrease in pressure at this moment, 
before increasing again with ascending ejection.   
 
 
 
Figure 21.  Changes in cardiac pump function (CO, LVSV, LVSW) and CVP during assist with the 
Parallel Driver using the regular driveline and the pneumatic capacitor driveline 
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Figure 22.  Changes in aortic and pulmonary pressures during assist with the Parallel Driver using 
the regular driveline and the pneumatic capacitor driveline 
 
 
 
4.3.2. Parallel vs. Series Activation of Pneumatic Disks, Baseline Heart 
The next group of results compare the activation of three pneumatic disks in 
parallel with the pneumatic capacitor driveline, versus activation of the pneumatic disks 
in series (without a driveline capacitor).  With the Series Driver, a single disk was activated 
during IVC, following by a delayed activation of the remaining two disks, timed to activate 
during ejection.   
Prior to the start of esmolol-induced acute failure, both Drivers were operated to 
evaluate the effect on the baseline heart.  Comparable changes were observed in the 
hemodynamic waveforms, and in almost all quantitatively measured hemodynamic 
parameters (see Figure 24 for hemodynamic waveform comparison).  The changes in CO,  
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Figure 23.  Hemodynamic waveform comparison between assist with the capacitor driveline (A), and 
the regular driveline (B) using the Parallel Driver; all gray waveforms represent standby, while the 
saturated colors reveal assist waveforms 
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Figure 24.  Physiologic signals to demonstrate change in LVP (blue), AoP (red), and AoF (green) with 
device assist during baseline conditions; (A) Standby and Assist conditions with the Parallel Driver; 
(B) Standby and Assist conditions with the Series Driver; note that neither driver shows a negative 
impact on normal physiologic profile of each physiologic parameter – only an increase in 
instantaneous magnitude; for both (A) and (B), the foreground saturated colors (Blue, Red, Green) 
represent the assist conditions, and the gray represent the corresponding standby conditions (sampled 
less than 1 min prior to each assist sample) 
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SV, PASP, PADP, PAMP, and CVP with assist using each Driver were nearly equivalent 
(Table 5).   The only notable difference in assist was the change in AoP; the parallel driver 
with the capacitor driveline had a higher reservoir pressure (150 mmHg vs. 60 mmHg), 
and thus a higher mean systolic assist pressure (7 mmHg vs. 4 mmHg).  This resulted in a 
slightly greater increase in SBP, DBP, and MAP with the parallel Driver (Table 5).  
Similarly, the increase in LVSW with assist was slightly more pronounced with the 
parallel Driver than the series Driver (Table 5).      
 
 
 
Table 5.  Summary of changes in hemodynamic parameters with assist during baseline conditions 
using the Parallel Driver and the Series Driver 
  PARALLEL DRIVER SERIES DRIVER 
  Standby Assist ∆ Standby Assist ∆ 
SBP (mmHg) 79 89 10 80 85 5 
DBP (mmHg) 59 68 9 60 63 3 
MAP (mmHg) 68 76 8 69 72 3 
PASP (mmHg) 17 16 -1 17 16 -1 
PADP (mmHg) 8 7 -1 9 8 -1 
PAMP (mmHg) 13 11 -2 13 12 -1 
CVP (mmHg) 6 6 0 5 5 0 
LV EDP (mmHg) 8 7 -1 8 7 -1 
LV SV (mL) 38 41 3 40 43 3 
CO (L/min) 3.9 4.1 0.2 4.3 4.5 0.2 
LV SW (mmHg*mL) 2874 3669 795 3089 3543 454 
EHDP   7     4   
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4.3.3. Parallel vs. Series Activation of Pneumatic Disks, Acute Failure 
Activation with each Driver resulted in the same increase in CO (+1.1 L/min) and 
SV (+13 mL) during acute heart failure, however the series driver resulted in more 
physiologic hemodynamic waveforms, compared to the parallel driver with a pneumatic 
capacitor.  This improvement to hemodynamic waveforms is shown in Figure 25.  
In addition to maintaining physiologic hemodynamics, assist with the series driver 
led to better arterial pressure results during acute heart failure.  While both Drivers resulted 
in a similar increase in aortic pressures, the change in pulmonary pressure was more ideal 
with the series driver.  Specifically, the parallel driver caused a 25 mmHg increase in the 
PASP, where the series driver resulted in a 4 mmHg increase.  This is related to the change 
in PAMP, which increased by 9 mmHg with the parallel driver, and only 1 mmHg with 
the series driver.  When considering the diastolic pressures, the changes with the parallel 
driver were dissimilar to the series driver; the DBP and the PADP both decreased by 6 
mmHg during assist with the parallel driver.  In contrast, the DBP increased by 2 mmHg, 
and the PADP decreased by only 1 mmHg with the series driver.  Finally, while assist with 
the series driver resulted in a 1 mmHg increase in mean CVP, assist with the parallel driver 
increased the mean CVP by 6 mmHg.  These results are summarized graphically in Figure 
26 and Figure 27. 
4.3.4. Parallel vs. Series Activation of Pneumatic Disks, Extreme Failure 
The parallel driver and the series driver were directly compared during extreme 
failure conditions, defined by a CO of <1 L/min during device standby.  Once again, the 
relative change in CO was comparable – a 1.1 L/min increase for the parallel driver and a 
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Figure 25.  Hemodynamic waveform comparison between assist with the Series Driver (A) and assist 
with the Parallel Driver during acute failure (B); notice the improved hemodynamics, particularly 
with the PAP and the aortic flow; for both (A) and (B), the foreground saturated colors (Blue, Red, 
Yellow, Green, Purple, and Black) represent the assist conditions, and the gray represent the 
corresponding standby conditions (sampled less than 1 min prior to each assist sample) 
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Figure 26.  Changes in aortic and pulmonary pressures during assist with the Parallel Driver using 
the pneumatic capacitor driveline compared to the Series Driver 
 
 
 
 
Figure 27.  Changes in cardiac pump function (CO, LVSV, LVSW) and CVP during assist with the 
Parallel Driver using the pneumatic capacitor driveline compared to the Series Driver 
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1.2 L/min increase for the series driver.  Additionally, the changes in MAP and PAMP 
were also similar for assist with each driver.  However once again, the series driver 
provided assist with more physiologic hemodynamics than the parallel driver.  These 
results are summarized in Table 6 and Figure 28.    
 
 
 
Table 6.  Summary of changes in hemodynamic parameters with assist during extreme failure 
conditions using the Parallel Driver and the Series Driver 
  PARALLEL DRIVER SERIES DRIVER 
  Standby Assist ∆ Standby Assist ∆ 
SBP (mmHg) 30 48 18 31 48 17 
DBP (mmHg) 21 14 -7 19 19 0 
MAP (mmHg) 23 28 5 23 30 7 
PASP (mmHg) 21 26 5 19 21 2 
PADP (mmHg) 18 15 -3 13 12 -1 
PAMP (mmHg) 19 20 1 15 16 1 
CVP (mmHg) 18 20 2 13 16 3 
LV EDP (mmHg) 19 19 0 14 14 0 
LV SV (mL) 4 21 17 9 21 12 
CO (L/min) 0.3 1.4 1.1 0.7 1.9 1.2 
LV SW (mmHg*mL) 93 752 659 216 932 716 
EHDP   15     20   
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Figure 28.  Hemodynamic waveform comparison between assist with the Series Driver (A) and assist 
with the Parallel Driver (B) during extreme failure conditions; notice the improved hemodynamics, 
particularly with the LVP, AoP, and the aortic flow; for both (A) and (B), the foreground saturated 
colors (Blue, Red, Yellow, Green, Purple, and Black) represent the assist conditions, and the gray 
represent the corresponding standby conditions (sampled less than 1 min prior to each assist sample) 
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4.4. Discussion 
This study was an investigation of methods for synchronizing device 
pressurization with heart contraction for the purpose of optimizing epicardial compressive 
assist on the acutely failing heart.  The methods for exploring synchrony with LV 
pressurization included adjustments to the Driver control software and hardware, with 
methods verified in two ovine acute heart failure model in vivo studies.   
While the introduction of a pneumatic capacitor resulted in slight improvements 
to the CO over the original Driveline, the most noteworthy outcomes of this investigation 
were the resulting hemodynamics during assist with the Series Driver.  Although it was 
expected that pressurization timing and rate would match IVC with Driver updates, 
achieving such remarkable similarity to physiologic hemodynamics was surprising.   
Other groups have reported methods of customizable DCC assist.  First, Hotei et 
al reported using a %Systole parameter to adjust the duration and onset timing of LV assist 
in a canine LV failure model.19  Their model was NaOH injection into the LV free wall 
myocardium to induce necrosis; the device was sutured over the region of necrotic tissue.  
They activated their device with no delay (no delay of activation from R-wave trigger) 
and a duration that was 40% of the RR interval (full systole), as well as limiting assist to 
the first 20% of RR (early systole assist) and delaying assist by 20% of RR (late systole 
assist).  It is interesting to note that they observed the greatest efficacy when assist was 
delayed by 20% of the RR interval, as this can be compared to the second stage of 
pneumatic disk activation with the Series Driver, or assist during ejection.  The Hotei 
group reported significant assist during IVC (as indicated by increases in peak LV dP/dt) 
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with early systole activation and minimal effect with late systole activation; in contrast, 
they observed the greatest increase in CO with assist during late systole, and minimal 
change with assist limited to early systole.  The results of our study show that by 
combining the epicardial compression into two phases, heart assist is optimized.  
Additionally, it is hypothesized that as the heart recovers, assist may only be needed with 
IVC, and for this reason, customizable stages of assist are favorable.  
More recently, the Roche et al group reported an updated DCC device that is 
designed to combine circumferential compression with active twisting.12  Although they 
describe a highly customizable pneumatic pressure control system and report comparable 
increases in CO to the present study results, the aortic flow waveforms appear to deviate 
significantly from the baseline hemodynamics.  
Efficacy of the driver was the focus of this study, yet practical considerations were 
also utilized in driver design. Specifically, the capacitor component was added to smooth 
the pressure spike created by the parallel driver configuration, and then the series driver 
was developed to obtain a more uniform pressurization during systole without the need 
for the capacitor component. It is desirable to eliminate the capacitor component with a 
software change because a system with fewer components is potentially more robust. 
4.4.1. Study Limitations 
While the data from the sections reporting a comparison of the Parallel Driver to 
the Series Driver under baseline conditions and extreme failure conditions are from the 
same animal, the results during normal acute failure conditions are from two separate 
animal studies.  It is possible that comparisons here are limited by variations in animal 
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response to esmolol and slight variations in the construction of the EpicHeart™ 
Implantable (EHI) between the two animals.   There were no studies during which the 
parallel and series drivers were both operated under normal failure conditions, as an 
unexpected animal response to high dose of esmolol occurred in the study intended to 
compare these two versions of the Driver.  However, the samples compared are from as 
similar as possible failure conditions, and equal reservoir pressure settings. 
Additionally, sample sizes for this investigation were limited by having multiple 
study aims in the protocol, as well as various unforeseen study complications.  A 
significant amount of time was devoted to assessing assist on the healthy heart as a result 
of updates to the EHI between studies.  While the resulting increases in cardiac 
performance and physiologic waveforms on the healthy heart were remarkable, the time 
devoted to this study aim limited the amount of time devoted to other study aims.    
One limitation of the Driver is the numerous user-defined parameters, as they 
introduce risk of operator error; for example, there is no feedback between the ECG QT 
duration (systole) and the driver software.  Because of this, the user is responsible for 
measuring systole and determining a proper systolic duration, and properly updating the 
corresponding driver parameter.  Finally, while the increased assist duration (AD) 
improved the CO, this parameter limited the maximum operational rate of assist; as the 
TAD+ID was increased (AD), the maximum sustainable HR decreased.  If the animal was 
tachycardic, the AD may be limited to a value below the ideal assist duration.  Efforts will 
be made to optimize the system to accommodate higher heart rates, as many heart failure 
patients are commonly tachycardic.   
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4.5. Conclusion 
The results of this study show that not only does the EpicHeart™ Device assist the 
heart during acute failure, but that it can be done in a manner that mimics the innate cardiac 
pressurization and hemodynamics.  This element of direct cardiac compression assist is 
vital to encouraging healthy growth and remodeling, and potentially bridge-to-recovery.    
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5. SUMMARY 
 
In summary, an innovative heart assist technology currently under investigation 
has been presented for potential use in heart failure therapy.  Proof-of-concept studies 
completed prior to this work were encouraging, but lacked repeated results, justifying the 
need for additional acute studies.  The results of these additional studies were reported 
here, and show a 75% recovery of baseline CO, on average.  This demonstrates the 
efficacy of the device to provide an increase in the CO during acute heart failure.   Still, 
questions remain regarding the efficacy of the device over longer durations, as well as in 
chronic heart failure conditions.  These questions will be the topic of future investigations.  
The in vivo studies for evaluation of device efficacy were coupled with the 
development of a device simulation tool.  A validated simulation of the device will be 
invaluable when transitioning from preclinical animal models to human trials.  The 
simulation data analyzed here for verification of performance specifications revealed 
minimal variation between in vivo and simulated hemodynamic effects of device assist.  
As this was a pilot study, more studies are needed to investigate the simulation parameters 
considered beyond the scope of this work.  Optimistically, this simulation tool will provide 
clinical professionals with insight regarding which patients will benefit the most from 
therapy with this epicardial heart assist device.  
The knowledge gained from this study will guide future development of the device, 
with the ultimate goal of device therapy for heart recovery. 
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Table A 1.  Summary of in vivo sources for each Patient Simulator input 
PARAMETER STUDY 1 STUDY 2 STUDY 3 STUDY 4 
HR Rate of Dual P Millar Rate of Dual P Millar Rate of Dual P Millar Rate of Dual P Millar 
EF AoF Probe (CO) & RVEDV AoF Probe (CO) & RVEDV AoF Probe (CO) & RVEDV AoF Probe (CO) & RVEDV 
TH CT Data - Constant CT Data - Constant CT Data - Constant CT Data - Constant 
CO Ao Flow Probe Ao Flow Probe Ao Flow Probe Ao Flow Probe 
CVP Swan-Ganz Swan-Ganz Swan-Ganz Swan-Ganz 
PAP S/D Swan-Ganz Swan-Ganz Estimated Estimated 
PAPM Swan-Ganz Swan-Ganz Estimated Estimated 
PCWP use LVP EDP (Millar) use LVP EDP (Millar) use LVP EDP (Millar) use LVP EDP (Millar) 
AOP S/D Dual P Millar Dual P Millar Dual P Millar Dual P Millar 
AOPM Dual P Millar Dual P Millar Dual P Millar Dual P Millar 
RA EDV CT Data - Constant CT Data - Constant CT Data - Constant CT Data - Constant 
LA EDV CT Data - Constant CT Data - Constant CT Data - Constant CT Data - Constant 
RV EDV CT Data - Constant CT Data - Constant CT Data - Constant CT Data - Constant 
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Table A 2.  Summary of hemodynamic outputs evaluated during this pilot investigation of the Harvi-CorInnova simulation application 
OUTPUT STUDY 1 STUDY 2 STUDY 3 STUDY 4 
AoP s/d/m Dual P Millar Dual P Millar Dual P Millar Dual P Millar 
PAP s/d/m Swan-Ganz Swan-Ganz Estimated Estimated 
LAP s/d/m exclude from analysis exclude from analysis exclude from analysis exclude from analysis 
RAP s/d/m exclude from analysis exclude from analysis exclude from analysis exclude from analysis 
PWP use LVP EDP use LVP EDP use LVP EDP use LVP EDP 
CVP Swan-Ganz Swan-Ganz Swan-Ganz Swan-Ganz 
EDV LV/RV exclude from analysis exclude from analysis exclude from analysis exclude from analysis 
EDP LV/RV LV only - Dual P Millar LV only - Dual P Millar LV only - Dual P Millar LV only - Dual P Millar 
ESV LV/RV exclude from analysis exclude from analysis exclude from analysis exclude from analysis 
ESP LV/RV exclude from analysis exclude from analysis exclude from analysis exclude from analysis 
SV LV/RV LV only - flow probe LV only - flow probe LV only - flow probe LV only - flow probe 
CO LV/RV LV only - flow probe LV only - flow probe LV only - flow probe LV only - flow probe 
SW LV/RV LV – flow probe/Millar LV – flow probe/Millar LV – flow probe/Millar LV – flow probe/Millar 
CPO LV/RV LV – flow probe/Millar LV – flow probe/Millar LV – flow probe/Millar LV – flow probe/Millar 
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Figure A 1.  Hemodynamic waveform comparison between in vivo (A) and simulation assist (B); figure shows left heart pressures (LVP and 
AoP) as well as DCC assist pressure in vivo and in simulation 
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Figure A 2.  Hemodynamic waveform comparison between in vivo aortic flow (A) and simulated aortic flow (B); both device standby and device 
assist conditions are plotted 
